Progression in smoldering Waldenstrom macroglobulinemia: long-term results

The purpose of this study was to define the risk of progression and survival of patients with smoldering Waldenstrom macroglobulinemia (SWM). SWM is defined clinically as having a serum monoclonal IgM protein >= 3 g/dL and/ or >= 10% bone marrow lymphoplasmacytic infiltration but no evidence of end-organ damage (anemia, constitutional symptoms, hyperviscosity, lymphadenopathy, or hepatosplenomegaly). We searched a computerized database and reviewed the medical records of all patients at Mayo Clinic who fulfilled the criteria of SWM between 1974 and 1995. During 285 cumulative person-years of follow-up of the 48 patients with SWM(median, 15.4 years), 34 (71%) progressed to symptomatic Waldenstrom macroglobulinemia (WM) requiring treatment, one to primary amyloidosis, and one to lymphoma (total, 75%). The cumulative probability of progression to symptomatic WM, amyloidosis, or lymphoma was 6% at 1 year, 39% at 3 years, 59% at 5 years, and 68% at 10 years. The major risk factors for progression were percentage of lymphoplasmacytic cells in the bone marrow, size of the serum M-spike, and the hemoglobin value. Patients with SWM should be followed and not treated until symptomatic WM develops. Treatment on a clinical trial for those at greatest risk of progression should be considered. (Blood. 2012; 119(19):4462-4466)